Partnering and collaboration for pharma, biotechs, healthcare and investors
 |
 |
 |
|
 |
|
 |
|
 |
EUROPE’S LARGEST VACCINE PARTNERING EVENT
Do you want to meet over 400 senior vaccine professionals to forge new partnerships and discover new commercial opportunities?
For the 13th year running delegates from all parts of the vaccine value chain come to World Vaccine Congress Lyon to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior congresses have produced many highly successful business partnerships.
The event at a glance in 2012:
- Government immunization priorities
- NGO collaboration models and funding
- Public and private vaccine investment mechanisms
- Prophylactic and Therapeutic R&D evolution
- Search and Develop (S&D) innovation and ‘Open Innovation’ models
- Vaccine corporate growth strategies
- Vaccine licensing and acquisition strategies
- Business development strategies and business models
- Vaccine deal making strategies
- Reimbursement issues and cost effectiveness strategies
- Vaccine market entry strategies and major vaccine market evolution
- New markets and opportunities in emerging markets
Innovation, licensing and collaboration opportunities for pharmas, biotechs and investors:
Build partnerships, licenses and deal-making options as a spring board to advance R&D portfolios. Learn about:
- How to position the asset to attract a deal
- Biotech business models for faster returns
- Unconventional deals to herculean strategies
- Deal trends under the microscope – early, joint lead, late stage and licensing
- Navigating the risk averse licensing environment
- Limiting the risk on in-licensed programs
- Risk management strategies and implications for innovators
- How best to strategise with licensing partners
- Risk reduction deal structures
- Alternative and novel exit pathways
Production and manufacture process optimization for pharma, biotech and contract partners
Adopt production capabilities and establish robust and efficient manufacturing processes for vaccine development and manufacturing advances. Learn about:
- New manufacturing strategy selection and adoption
- Overcoming process development challenges for new vaccines
- Upstream and downstream process integration
- Upstream process collection and harvesting
- Commercial scale clarification, purification and inactivation
- Efficient formulation final fill and finish
- Controlling costs of complex manufacturing processes
- Novel technologies redesigning vaccine phases
- Entrenching disposable / single-use system application
- Enabling efficient outsourced manufacturing activities
- Promoting vaccine production in developing countries
Influenza policy, planning, research & development and stakeholder partnerships
Bridge the scientific potential and the commercial reality of influenza demand and tackle the critical scientific, strategic and commercial challenges associated with assigning resources to building viable and sustainable influenza portfolios.
- Governmental immunisation requirements, market access and uptake
- Seasonal, pre-pandemic and pandemic preparedness strategies and contracting
- Regional regulatory procedures and risk management plans
- Encouraging global Influenza R&D through public/private partnerships
- Corporate growth strategies and R&D pipeline models
- Seasonal, Pandemic and Universal Influenza research and clinical development
- Seasonal and Pandemic Influenza vaccine production and manufacture
- Regulatory approval and authorisation / standardisation
